PDF herunterladen
Thromb Haemost
DOI: 10.1055/a-2717-5994
Letter to the Editor

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Platelet Reactivity in Patients with Atherosclerotic Cardiovascular Disease: A Pooled Analysis of Two Randomized Double-blind Placebo-controlled Studies

Authors

  • Luis Ortega-Paz 

    1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States

  • Yasushi Ueki 

    2   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Claudio Laudani 

    1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States
    3   Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico “Rodolico – San Marco,” University of Catania, Catania, Italy

  • Sylvain Losdat

    4   Department of Clinical Research, Bern, University of Bern, Bern, Switzerland

  • Francesco Franchi

    1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States

  • Ryota Kakizaki

    2   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Fabiana Rollini

    1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States

  • Jonas Häner

    2   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Lorenz Räber

    2   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Dominick J. Angiolillo 

    1   Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States
Weitere Informationen
   Lizenzen und Reprints


Graphical Abstract

Preview

Data Availability Statement

All data are available upon reasonable request to the corresponding author.


Supplementary Material



Publikationsverlauf

Eingereicht: 07. März 2025

Angenommen: 07. Oktober 2025

Accepted Manuscript online:
10. Oktober 2025

Artikel online veröffentlicht:
21. Oktober 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Giordano S, Franchi F, Rollini F. et al. Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy. Minerva Cardiol Angiol 2024; 72 (05) 489-505
    CrossrefPubMedSuche in Google Scholar
  • 2 Navarese EP, Kolodziejczak M, Winter M-P. et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study. Int J Cardiol 2017; 227: 644-649
    CrossrefPubMedSuche in Google Scholar
  • 3 Sabatine MS, Giugliano RP, Keech AC. et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376 (18) 1713-1722
    CrossrefPubMedSuche in Google Scholar
  • 4 Franchi F, Ortega-Paz L, Rollini F. et al. Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study. EuroIntervention 2023; 18 (15) 1254-1265
    PubMedSuche in Google Scholar
  • 5 Tierney JF, Stewart LA, Clarke M. on behalf of the Cochrane Individual Participant Data Meta-analysis Methods Group. Individual participant data. In: Higgins JPT, Thomas J, Chandler J. et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons; 2019: 643-658
    Suche in Google Scholar
  • 6 Ueki Y, Häner JD, Losdat S. et al. Effect of alirocumab added to high-intensity statin on platelet reactivity and noncoding RNAs in patients with AMI: a substudy of the PACMAN-AMI trial. Thromb Haemost 2024; 124 (06) 517-527
    Thieme ConnectPubMedSuche in Google Scholar
  • 7 Cammisotto V, Baratta F, Castellani V. et al. Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways. Int J Mol Sci 2021; 22 (13) 7193
    CrossrefPubMedSuche in Google Scholar
  • 8 Räber L, Ueki Y, Otsuka T. et al; PACMAN-AMI collaborators. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA 2022; 327 (18) 1771-1781
    CrossrefPubMedSuche in Google Scholar